Literature DB >> 30247601

Statistical Learning Methods to Determine Immune Correlates of Herpes Zoster in Vaccine Efficacy Trials.

Peter B Gilbert1, Alexander R Luedtke1.   

Abstract

Using Super Learner, a machine learning statistical method, we assessed varicella zoster virus-specific glycoprotein-based enzyme-linked immunosorbent assay (gpELISA) antibody titer as an individual-level signature of herpes zoster (HZ) risk in the Zostavax Efficacy and Safety Trial. Gender and pre- and postvaccination gpELISA titers had moderate ability to predict whether a 50-59 year old experienced HZ over 1-2 years of follow-up, with equal classification accuracy (cross-validated area under the receiver operator curve = 0.65) for vaccine and placebo recipients. Previous analyses suggested that fold-rise gpELISA titer is a statistical correlate of protection and supported the hypothesis that it is not a mechanistic correlate of protection. Our results also support this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30247601      PMCID: PMC6151089          DOI: 10.1093/infdis/jiy421

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

2.  Super learner.

Authors:  Mark J van der Laan; Eric C Polley; Alan E Hubbard
Journal:  Stat Appl Genet Mol Biol       Date:  2007-09-16

3.  A framework for assessing immunological correlates of protection in vaccine trials.

Authors:  Li Qin; Peter B Gilbert; Lawrence Corey; M Juliana McElrath; Steven G Self
Journal:  J Infect Dis       Date:  2007-10-02       Impact factor: 5.226

4.  The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.

Authors:  Olivia Hammond; Yue Wang; Tina Green; Joseph Antonello; Robert Kuhn; Clifford Motley; Philip Stump; Beverly Rich; Narendra Chirmule; Rocio D Marchese
Journal:  J Med Virol       Date:  2006-12       Impact factor: 2.327

5.  Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

Authors:  Kenneth E Schmader; Myron J Levin; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino
Journal:  Clin Infect Dis       Date:  2012-01-30       Impact factor: 9.079

6.  Global analyses of human immune variation reveal baseline predictors of postvaccination responses.

Authors:  John S Tsang; Pamela L Schwartzberg; Yuri Kotliarov; Angelique Biancotto; Zhi Xie; Ronald N Germain; Ena Wang; Matthew J Olnes; Manikandan Narayanan; Hana Golding; Susan Moir; Howard B Dickler; Shira Perl; Foo Cheung
Journal:  Cell       Date:  2014-04-10       Impact factor: 41.582

7.  Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.

Authors:  Peter B Gilbert; Erin E Gabriel; Xiaopeng Miao; Xiaoming Li; Shu-Chih Su; Janie Parrino; Ivan S F Chan
Journal:  J Infect Dis       Date:  2014-05-13       Impact factor: 5.226

  7 in total
  3 in total

1.  CMV viral load kinetics as surrogate endpoints after allogeneic transplantation.

Authors:  Elizabeth R Duke; Brian D Williamson; Bhavesh Borate; Jonathan L Golob; Chiara Wychera; Terry Stevens-Ayers; Meei-Li Huang; Nicole Cossrow; Hong Wan; T Christopher Mast; Morgan A Marks; Mary E Flowers; Keith R Jerome; Lawrence Corey; Peter B Gilbert; Joshua T Schiffer; Michael Boeckh
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 2.  The COVID-19 Vaccine Landscape.

Authors:  Till Koch; Anahita Fathi; Marylyn M Addo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Comparison of machine learning methods for estimating case fatality ratios: An Ebola outbreak simulation study.

Authors:  Alpha Forna; Ilaria Dorigatti; Pierre Nouvellet; Christl A Donnelly
Journal:  PLoS One       Date:  2021-09-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.